

ZENOTECH LABORATORIES LIMITED

 8-2-120/112/88-89/P/2, 4th Floor, Park View Estate, Road No.2, Banjara Hills
 Hyderabad - 500 034

Unaudited standalone financial results for the quarter ended June 30, 2009


(Rs. lakhs)

		Quarter ended		Year ended
		30/Jun/09	30/Jun/08	31/Mar/09
		Unaudited	Unaudited	Audited
1	a. Net Sales/Income from operations	107.18	277.05	602.32
	b. Other operating income	-	-	
	Total income	107.18	277.05	602.32
2	Expenditure			
	a. (Increase) / decrease in stock in trade and work in progress	22.56	6.01	171.88
	b. Consumption of raw materials	54.98	121.84	299.04
	c. Other expenditure	87.48	85.02	411.55
	d. Employee cost	116.95	126.78	622.25
	e. Administration, selling and distribution and other expenses	49.92	73.64	384.29
	f. Product development expenses	33.53	115.32	310.47
	g. Depreciation	79.21	71.36	294.07
	h. Amortisation of miscellaneous expenditure including product development expenditure	29.85	29.86	119.41
	i. Total	474.48	629.83	2,612.96
3	Profit (+)/ loss (-) from operations before other income, interest and exceptional items (1 - 2)	(367.30)	(352.78)	(2,010.64)
4	Other income	91.18	131.37	515.47
5	Profit (+)/ loss (-) before interest and exceptional items (3 + 4)	(276.12)	(221.41)	(1,495.17)
6	Interest	64.83	44.60	201.81
7	Profit (+)/ loss (-) after interest and exceptional items (5 - 6)	(340.95)	(266.01)	(1,696.98)
8	Exceptional items	-	-	465.48
9	Profit (+)/ loss (-) from ordinary activities before tax (7+ 8)	(340.95)	(266.01)	(2,162.46)
10	Tax expense	0.97	0.82	4.61
11	Net profit (+)/ loss (-) from ordinary activities after tax (9 - 10)	(341.92)	(266.83)	(2,167.07)
12	Extraordinary item (net of tax expenses Rs.)	-	-	
13	Net profit (+)/ loss (-) for the period (11 - 12)	(341.92)	(266.83)	(2,167.07)
14	Paid-up equity share capital (Face value of Rs.10/- per equity share)	3,442.50	3,442.50	3,442.50
15	Reserves excluding revaluation reserves as per balance sheet of previous accounting year			11,641.76
16	Earnings per share (not annualized) (Rs.)			
	a. Before extraordinary items			
	- Basic	(0.99)	(0.78)	(6.30)
	- Diluted	(0.99)	(0.78)	(6.30)
	b. After extraordinary items			
	- Basic	(0.99)	(0.78)	(6.30)
	- Diluted	(0.99)	(0.78)	(6.30)
17	Public shareholding			
	- Number of shares	9,428,311	9,430,711	9,428,311
	- Percentage of shareholding	27.39%	27.39%	27.39%
18	Promoter Shareholding - No. of Shares			
	a) Pledged / Encumbered			
	- No of shares	680,000		850,000
	- Percentage of shares (as a % of the total shareholding of promoter & promoter group)	7.67%		9.58%
	- Percentage of shares (as a % of the total shareholding of the Company)	1.98%		2.47%
	b) Non-encumbered			
	- No of shares	8,189,396		8,019,396
	- Percentage of shares (as a % of the total shareholding of promoter & promoter group)	18.09%		16.18%
	- Percentage of shares (as a % of the total shareholding of the Company)	23.78%		23.29%

Notes:

- The above results were approved by the Board of Directors at its meeting held on November 16, 2009.
- The Company operated in one segment only - Pharmaceuticals.
- In the year 2007-08, in terms of its shareholders resolution dated 8th November, 2007 the Company has issued 54,89,536 equity shares of Rs.10/- each to M/s. Ranbaxy Laboratories Limited at a premium of Rs. 150/- per share on preferential allotment basis on 23rd November, 2007. Out of the proceeds of Rs.8783.25 lakhs from the aforesaid issue, the Company utilised the funds for repayment of secured and unsecured loans, to meet Product development expenditure and the working capital needs of the company etc., Balance unutilised amount of Rs.2736.57 lakhs has been invested in Fixed Deposits with Banks.
- During the quarter under review, the following is the status of investor compliants : opening balance : nil; received during the quarter : nil; resolved during the quarter: nil; closing balance: nil.
- The public shareholding as mentioned at point no.17 above includes only general public. Ranbaxy Laboratories Limited's shareholding in the Company, constituting 46.85% has not been included in the above, as opinion regarding status of shareholder is awaited.
- Figures have been regrouped/reclassified and recast wherever necessary.

By order of the Board



 Dr. Jayaram Chigurupati
 Managing Director

Place: Hyderabad

Date: 16/11/2009